Shijiazhuang Yiling Pharmaceutical Co., Ltd. Logo

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

002603.SZ

(2.8)
Stock Price

17,12 CNY

1.74% ROA

2.38% ROE

113.89x PER

Market Cap.

31.526.297.700,00 CNY

16.48% DER

1.59% Yield

3.44% NPM

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Stock Analysis

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (23.22%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

3 DER

The stock has a low debt to equity ratio (14%), which means it has a small amount of debt compared to the ownership it holds

4 Assets Growth

This company's revenue has experienced steady growth over the last five years, indicating a reliable and prosperous financial trajectory.

5 Dividend

Shareholders can rely on the company's remarkable dividend history, consistently paying dividends for the past five years, demonstrating a steadfast dedication to rewarding investors.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is undervalued (137), making it an appealing investment prospect with its intrinsic value surpassing the current market price.

7 PBV

The stock's high Price-to-Book Value (P/BV) ratio (3.25x) suggests it's overvalued, potentially making it an expensive investment.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

10 Graham Number

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Revenue
Year Revenue Growth
2008 938.555.953
2009 1.632.330.986 42.5%
2010 1.649.320.072 1.03%
2011 1.953.211.430 15.56%
2012 1.648.676.344 -18.47%
2013 2.490.161.533 33.79%
2014 2.921.157.257 14.75%
2015 3.184.752.368 8.28%
2016 3.820.158.728 16.63%
2017 4.081.266.654 6.4%
2018 4.814.557.822 15.23%
2019 5.825.294.498 17.35%
2020 8.782.479.676 33.67%
2021 10.116.793.937 13.19%
2022 12.532.841.028 19.28%
2023 7.136.467.068 -75.62%
2023 10.183.185.309 29.92%
2024 8.216.876.644 -23.93%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2008 0
2009 0 0%
2010 0 0%
2011 82.174.330 100%
2012 111.051.186 26%
2013 139.378.699 20.32%
2014 139.747.508 0.26%
2015 154.630.913 9.63%
2016 187.724.919 17.63%
2017 217.441.118 13.67%
2018 316.709.728 31.34%
2019 390.745.752 18.95%
2020 654.389.038 40.29%
2021 792.162.704 17.39%
2022 1.032.006.459 23.24%
2023 764.400.487 -35.01%
2023 819.214.482 6.69%
2024 814.432.940 -0.59%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 76.818.163
2009 101.906.865 24.62%
2010 153.589.557 33.65%
2011 34.222.892 -348.79%
2012 58.450.101 41.45%
2013 66.513.485 12.12%
2014 71.997.211 7.62%
2015 101.800.245 29.28%
2016 56.645.894 -79.71%
2017 59.963.437 5.53%
2018 83.053.733 27.8%
2019 114.599.613 27.53%
2020 166.585.267 31.21%
2021 165.913.294 -0.41%
2022 158.241.849 -4.85%
2023 1.451.178.473 89.1%
2023 185.710.375 -681.42%
2024 -289.119.811 164.23%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. EBITDA
Year EBITDA Growth
2008 178.394.464
2009 395.648.241 54.91%
2010 421.635.922 6.16%
2011 616.877.556 31.65%
2012 288.890.338 -113.53%
2013 356.484.082 18.96%
2014 466.122.427 23.52%
2015 631.955.896 26.24%
2016 857.085.162 26.27%
2017 886.116.510 3.28%
2018 958.673.054 7.57%
2019 971.566.852 1.33%
2020 1.767.511.703 45.03%
2021 2.017.624.695 12.4%
2022 3.375.643.834 40.23%
2023 697.314.843 -384.09%
2023 2.157.205.610 67.68%
2024 1.678.844.120 -28.49%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Gross Profit
Year Gross Profit Growth
2008 558.824.828
2009 995.524.403 43.87%
2010 1.094.617.220 9.05%
2011 1.335.520.593 18.04%
2012 1.124.634.059 -18.75%
2013 1.659.659.903 32.24%
2014 1.843.505.865 9.97%
2015 2.020.341.136 8.75%
2016 2.532.460.402 20.22%
2017 2.777.352.781 8.82%
2018 3.183.732.926 12.76%
2019 3.719.081.942 14.39%
2020 5.664.067.086 34.34%
2021 6.435.798.883 11.99%
2022 7.992.268.977 19.47%
2023 4.157.728.642 -92.23%
2023 5.588.023.417 25.6%
2024 4.300.577.732 -29.94%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Net Profit
Year Net Profit Growth
2008 122.117.123
2009 297.182.764 58.91%
2010 315.559.119 5.82%
2011 454.071.087 30.5%
2012 185.806.390 -144.38%
2013 244.291.460 23.94%
2014 354.495.205 31.09%
2015 430.491.010 17.65%
2016 542.023.195 20.58%
2017 540.705.102 -0.24%
2018 599.221.880 9.77%
2019 606.501.070 1.2%
2020 1.218.737.679 50.24%
2021 1.343.856.007 9.31%
2022 2.362.756.484 43.12%
2023 610.653.579 -286.92%
2023 1.352.379.242 54.85%
2024 906.116.760 -49.25%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 1 0%
2021 1 0%
2022 1 100%
2023 0 0%
2023 1 0%
2024 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Free Cashflow
Year Free Cashflow Growth
2008 81.907.543
2009 107.641.454 23.91%
2010 14.699.708 -632.27%
2011 -586.382.017 102.51%
2012 -226.760.111 -158.59%
2013 -354.505.678 36.03%
2014 -344.288.269 -2.97%
2015 -346.556.215 0.65%
2016 258.614.487 234%
2017 -65.694.795 493.66%
2018 -114.861.737 42.81%
2019 -385.502.614 70.2%
2020 441.393.386 187.34%
2021 -144.865.277 404.69%
2022 3.273.756.001 104.43%
2023 -117.542.438 2885.17%
2023 -621.983.215 81.1%
2024 104.752.007 693.77%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
2008 210.177.689
2009 318.211.329 33.95%
2010 299.717.830 -6.17%
2011 -408.486.085 173.37%
2012 70.128.569 682.48%
2013 55.322.427 -26.76%
2014 105.904.047 47.76%
2015 131.877.728 19.7%
2016 631.641.569 79.12%
2017 114.652.887 -450.92%
2018 72.366.629 -58.43%
2019 68.925.449 -4.99%
2020 1.586.172.733 95.65%
2021 528.693.714 -200.02%
2022 3.487.736.416 84.84%
2023 193.291.555 -1704.39%
2023 -535.915.250 136.07%
2024 146.903.431 464.81%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
2008 128.270.146
2009 210.569.875 39.08%
2010 285.018.121 26.12%
2011 177.895.932 -60.22%
2012 296.888.680 40.08%
2013 409.828.105 27.56%
2014 450.192.316 8.97%
2015 478.433.943 5.9%
2016 373.027.081 -28.26%
2017 180.347.682 -106.84%
2018 187.228.366 3.68%
2019 454.428.063 58.8%
2020 1.144.779.347 60.3%
2021 673.558.991 -69.96%
2022 213.980.415 -214.78%
2023 310.833.993 31.16%
2023 86.067.965 -261.15%
2024 42.151.424 -104.19%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Equity
Year Equity Growth
2008 484.032.487
2009 790.547.778 38.77%
2010 1.091.034.327 27.54%
2011 3.701.641.763 70.53%
2012 3.844.971.033 3.73%
2013 4.258.340.814 9.71%
2014 4.554.101.830 6.49%
2015 4.827.400.437 5.66%
2016 5.332.624.904 9.47%
2017 7.111.788.738 25.02%
2018 7.563.660.883 5.97%
2019 7.952.544.645 4.89%
2020 8.923.352.896 10.88%
2021 9.072.169.267 1.64%
2022 10.930.271.820 17%
2023 11.437.995.200 4.44%
2023 11.848.044.899 3.46%
2024 11.463.430.539 -3.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Assets
Year Assets Growth
2008 831.911.768
2009 1.509.440.515 44.89%
2010 1.771.111.343 14.77%
2011 4.225.417.265 58.08%
2012 4.165.722.012 -1.43%
2013 4.658.033.725 10.57%
2014 5.087.911.365 8.45%
2015 5.706.958.738 10.85%
2016 6.250.452.402 8.7%
2017 7.887.369.191 20.75%
2018 8.557.219.469 7.83%
2019 9.069.396.868 5.65%
2020 11.492.337.701 21.08%
2021 12.904.842.340 10.95%
2022 16.336.112.689 21%
2023 16.979.326.536 3.79%
2023 17.435.003.797 2.61%
2024 16.951.526.200 -2.85%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Liabilities
Year Liabilities Growth
2008 347.879.280
2009 718.892.735 51.61%
2010 680.077.015 -5.71%
2011 523.775.502 -29.84%
2012 320.750.978 -63.3%
2013 399.692.910 19.75%
2014 533.809.535 25.12%
2015 879.558.300 39.31%
2016 917.827.497 4.17%
2017 775.580.452 -18.34%
2018 993.558.585 21.94%
2019 1.116.852.221 11.04%
2020 2.568.984.805 56.53%
2021 3.832.673.071 32.97%
2022 5.405.840.867 29.1%
2023 5.188.957.516 -4.18%
2023 5.586.958.898 7.12%
2024 5.123.401.996 -9.05%

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
4.81
Net Income per Share
0.17
Price to Earning Ratio
113.89x
Price To Sales Ratio
3.92x
POCF Ratio
-136.34
PFCF Ratio
-60.09
Price to Book Ratio
2.75
EV to Sales
4.01
EV Over EBITDA
46.31
EV to Operating CashFlow
-139.33
EV to FreeCashFlow
-61.41
Earnings Yield
0.01
FreeCashFlow Yield
-0.02
Market Cap
31,53 Bil.
Enterprise Value
32,22 Bil.
Graham Number
5.06
Graham NetNet
-0.33

Income Statement Metrics

Net Income per Share
0.17
Income Quality
-0.84
ROE
0.02
Return On Assets
0.02
Return On Capital Employed
0.03
Net Income per EBT
0.7
EBT Per Ebit
0.96
Ebit per Revenue
0.05
Effective Tax Rate
0.32

Margins

Sales, General, & Administrative to Revenue
0.02
Research & Developement to Revenue
0.1
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.49
Operating Profit Margin
0.05
Pretax Profit Margin
0.05
Net Profit Margin
0.03

Dividends

Dividend Yield
0.02
Dividend Yield %
1.59
Payout Ratio
6.26
Dividend Per Share
0.3

Operating Metrics

Operating Cashflow per Share
-0.14
Free CashFlow per Share
-0.31
Capex to Operating CashFlow
-1.27
Capex to Revenue
0.04
Capex to Depreciation
1.55
Return on Invested Capital
0.02
Return on Tangible Assets
0.02
Days Sales Outstanding
144.93
Days Payables Outstanding
172.8
Days of Inventory on Hand
172.34
Receivables Turnover
2.52
Payables Turnover
2.11
Inventory Turnover
2.12
Capex per Share
0.18

Balance Sheet

Cash per Share
0,73
Book Value per Share
7,08
Tangible Book Value per Share
6.46
Shareholders Equity per Share
6.87
Interest Debt per Share
1.16
Debt to Equity
0.16
Debt to Assets
0.11
Net Debt to EBITDA
0.99
Current Ratio
1.49
Tangible Asset Value
10,79 Bil.
Net Current Asset Value
1,41 Bil.
Invested Capital
10743025926
Working Capital
2,16 Bil.
Intangibles to Total Assets
0.06
Average Receivables
3,15 Bil.
Average Payables
1,94 Bil.
Average Inventory
1959145208.5
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Dividends
Year Dividends Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 1 100%
2022 0 0%
2023 1 0%
2024 0 0%

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Profile

About Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of medicine primarily in China. The company operates through Chemical and Biological Medicine, and Health Industry segments. It offers drugs for cardiac and premature ventricular beats, sinus bradycardia, chronic heart failure, integrated rhythm regulation, cold and respiratory, cardiovascular and cerebrovascular diseases, diabetes field, tumor medication, and others. The company sells its products through physical display and online. Shijiazhuang Yiling Pharmaceutical Co., Ltd. was founded in 1992 and is based in Shijiazhuang, China.

CEO
Mr. Xiang Jun Wu
Employee
13.958
Address
No. 238 Tianshan Street
Shijiazhuang, 050035

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Executives & BODs

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Executives & BODs
# Name Age
1 Ms. Wei Wang
Deputy GM & Director of Administrative Center
70
2 Ms. Rui Wu
Secretary of the Board & Non-Independent Director
70
3 Mr. Xiang Jun Wu
Chairman & GM
70
4 Mr. Wei Dong Xu
Executive Deputy Director of the Human Resources Center & Director
70
5 Mr. Chen Guang Li
Chief Financial Officer & Director
70
6 Ms. Qiu Lian Zhang
Deputy GM & Non-Independent Director
70
7 Mr. Xiaolin Zhou
Deputy GM & Director of the Supply Center
70

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Competitors